Navigation Links
PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
Date:5/21/2008

ients with CF."

About Cystic Fibrosis

Cystic fibrosis (CF) is among the most common life-threatening genetic disorders worldwide. According to the Cystic Fibrosis Foundation, CF affects approximately 30,000 adults and children in the United States and, according to the European Cystic Fibrosis Foundation, it affects a similar number of patients in Europe. CF occurs in approximately one of every 3,500 live births, with approximately 1,000 new cases diagnosed each year in the United States. There is a commercially available genetic test to determine if a patient's CF is caused by a nonsense mutation, and it is estimated that nonsense mutations are the cause of CF in approximately 10% of patients in the United States. There is currently no available therapy to correct defective CFTR production and function. Instead, available treatments for CF are designed to alleviate the symptoms of the disease. These treatments include chest physical therapy to clear the thick mucus from the lungs, antibiotics to treat lung infections and a mucus-thinning drug designed to reduce the number of lung infections and improve lung function. In addition, the majority of cystic fibrosis patients take pancreatic enzyme supplements to assist with food absorption in digestion. There is a significant unmet medical need for treatments for the underlying cause of CF. More information regarding CF is available through the Cystic Fibrosis Foundation (http://www.cff.org).

About PTC124

PTC124 is an orally delivered investigational new drug in Phase 2 clinical development for the treatment of genetic disorders due to nonsense mutations. Nonsense mutations are single-point alterations in the genetic code that prematurely stop the translation process, producing a shortened, non- functional protein. PTC124 has restored production of full-length, functional proteins in preclinical genetic disease models harboring nonsense mutations
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
2. PacificGMP Completes GMP Product Fill for Trius Therapeutics
3. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
4. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
5. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
6. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
7. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
8. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
11. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... STEPh, Inc., a full service medical communications ... web site ( http://www.stephreports.com ) dedicated to ... STEPh Reports STEPh Reports are comprehensive critical ... STEPh Report assesses the competitive landscape by individual drug ... and specific key issues.  STEPh Reports are written by ...
(Date:5/22/2013)... , May 22, 2013 MEDIFIRST SOLUTIONS, INC. ... update shareholders about some recent company developments. As Medifirst ... avenues of communication with shareholders. Integrating social media into ... Facebook page and will post updates on Twitter.  The ... is #medifirstusa. Says CEO ...
(Date:5/22/2013)... , May 22, 2013 Ranbaxy ... Sankyo Co., Ltd. (hereafter, Daiichi Sankyo), announced on ... in recent years to address past conduct under ... Daiichi Sankyo continues to support ... the conduct of the past which led to ...
Breaking Medicine Technology:Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site 2Medifirst Solutions, Inc. Announces Update To Shareholders 2
... 9, 2011 ProTron Technologies announces a new approach ... the patented Stethotron® Cerebral Stethoscope. In the ... In 50% of ruptured aneurysms, patients in the age ... of the major factors leading to aneurysm is vascular ...
... Westside Medical Imaging of Beverly Hills announces the ... a 3 Tesla magnet to monitor the effects of cholesterol ... Hooman Madyoon and Michael Duffy of ... adopted 3 Tesla magnetic resonance imaging (MRI) using specialized vascular ...
Cached Medicine Technology:Westside Medical Imaging Uses High Resolution Magnetic Imaging to Monitor Effects of Cholesterol Drugs on Atherosclerosis 2
(Date:5/22/2013)... Go Classy the Original Nudist Travel ... of their newest website http://www.Desire-Mexico.com . The seductively ... Desire Resorts have become the premier Nudist and Lifestyle ... total liberation while allowing you to enjoy a deluxe ... Classy Tours / Caribbean-Hideaways. He goes on to say ...
(Date:5/22/2013)... May 22 (HealthDay News) -- Fish oil supplements ... diabetes, new research suggests. The supplements, ... of a hormone called adiponectin that,s linked to ... this hormone in the bloodstream have also been ... "While prior animal studies found fish oil ...
(Date:5/22/2013)... 1,000 mg per day can help women live longer, ... Langsetmo, a Ph.D. Research Associate at McGill University, and ... Endocrinology and Metabolism in the Department of Medicine of ... Disorders axis at the Research Institute of the McGill ... Journal of Clinical Endocrinology & Metabolism (JCEM). ...
(Date:5/22/2013)... The newest member of TeethWhiteningforFree.com is Dr. ... Alabama graduate, Dr. Sanderson provides professional dental care to ... he extends complimentary teeth whitening to his patients who ... up. Only a dental professional can decide if the ... , Teeth whitening is an easy way ...
(Date:5/22/2013)... DiscountFurnaceFilter.com now offers a vast ... furnace filters, dehumidifiers, fans, aroma diffusers, dehumidifiers and ... Stadler Form's product line to their selection! Stadler ... aroma diffusers and dehumidifiers) to accentuate anyone’s home ... the perfect combination of design and functionality. Otto ...
Breaking Medicine News(10 mins):Health News:Go Classy Tours Announces the Launch of Their Newest Website for Desire Resorts Located in Mexico Clothing Optional/Aunaturel Resorts a Lovers Paradise 2Health News:Fish Oil Pills Might Cut Diabetes Risk, Researchers Say 2Health News:Calcium supplements linked to longer lifespans in women 2Health News:Dr. James Sanderson, Jr. Of SanDentistry in Hoover, Alabama Joins the TeethWhiteningforFree.com Family 2Health News:DiscountFurnaceFilter.com Now Offers Stadler Form Products - Providing Solutions to All Your Summer Needs 2
... 29 The National Patient,Safety Foundation,s theme this ... the importance of improving healthcare as a joint,effort ... Supporting National Patient Safety Awareness Week, March 2-8, ... ) urges communities to,actively partner with local hospitals ...
... Cardiogenesis,Corporation (Pink Sheets: CGCP), a leading developer ... today announced that,it will delay its earnings release ... full year ended December 31, 2007. The earnings ... Tuesday, March 4,2008., The Company noted that ...
... the Only Provider to Offer Practice Management and ... of Mental Health Care Providers, GREAT RIVER, ... provider of enterprise-wide software and services for health ... Therapist,Helper product suite and operations from Nightingale VantageMed,Corporation, ...
... PRINCETON, N.J., Feb. 29 Orchid Cellmark Inc.,(Nasdaq: ... testing,services, will release its fourth quarter and full year ... 7:00 am EST, and is,hosting a conference call and ... the same day. Management will discuss financial results for ...
... heart, liver and lung transplants at UCSF Medical ... according to new data compiled by the Scientific ... Released on January 11, the report measures performance ... facilities in the United States, including waiting list ...
... and benefits still outweigh risks, experts say , , FRIDAY, ... the risk for tendon problems, French researchers report. , ... rare, considering the huge number of statin prescriptions," wrote ... March issue of Arthritis Care and Research , ...
Cached Medicine News:Health News:Encision Supports National Patient Safety Awareness Week 2Health News:Cardiogenesis Corporation Reports Delay in Earnings Release and Conference Call 2Health News:Netsmart Technologies Acquires Largest Provider of Software for Private Practice Mental Health Providers and Therapists 2Health News:Netsmart Technologies Acquires Largest Provider of Software for Private Practice Mental Health Providers and Therapists 3Health News:Netsmart Technologies Acquires Largest Provider of Software for Private Practice Mental Health Providers and Therapists 4Health News:Orchid Cellmark to Announce Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008 2Health News:Survival rates exceed national averages for UCSF heart, liver and lung transplant programs 2Health News:Cholesterol-Lowering Statins Tied to Tendon Woes 2Health News:Cholesterol-Lowering Statins Tied to Tendon Woes 3
... the highest g-force ever. But optimal productivity ... Optima MAX combines maximum force, capacity, and ... that's worlds apart from any other system. ... enhanced efficiency, Optima takes productivity to the ...
... generating 694,000 x g at ... Beckman Coulter's Optima L-90K Ultracentrifuge ... separations in less time. This ... a broad range of superb ...
... With the ability to provide a simple, ... in lipemic samples), the Airfuge CLS delivers ... can be cleaned in 10 minutes, eliminating ... tabletop centrifuge: Reaches top speed in as ...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
Medicine Products: